Orion Oyj

ORNBV

FI0009014377

Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 12:00:01 2024-07-17 EDT			5-day change	1st Jan Change
40.76 ^EUR	-0.34%		-0.07%	+3.79%

07-17	Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint	CI
07-01	Orion, Merck & Co. Convert Agreement into Exclusive Global License to Opevesostat	MT

Orion Looks For Possible Sale Of Subsidiary Orion Diagnostica Oy

January 23, 2018 at 12:00 am

Orion Oyj (HLSE:ORNBV) is seeking to sell Orion Diagnostica Oy. Orion will investigate possible sale of Orion Diagnostica Oy.

Latest news about Orion Oyj

Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint	07-17	CI
Orion, Merck & Co. Convert Agreement into Exclusive Global License to Opevesostat	07-01	MT
Orion Upgrades FY24 Outlook After Modifying Agreement with Merck & Co	07-01	MT
Merck, Orion Convert Collaboration Into Exclusive License	07-01	DJ
Orion Corporation and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat	07-01	CI
Orion Oyj Revises Earnings Guidance for the Year 2024	07-01	CI
Orion Obtains License to Market Navamedic's Parkinson's Disease Drug in Europe	06-25	MT
Navamedic ASA and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe	06-24	CI
Orion Partners with Universities for Biotechnology Project in Finland	06-03	MT
Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025	05-07	CI
Orion Corporation Announces Appointments to Nomination Committee	04-26	CI
Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024	04-25
Orion Oyj Revises Earnings Guidance for the Year 2024	04-25	CI
Orion Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Orion to Continue Reviewing Outsources Options for Finnish Plant as Change Negotiations Complete	03-22	MT
Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024	03-22	CI
Orion Corporation Announces Board and Committee Appointment	03-20	CI
Orion Corporation Approves Board Appointments	03-20	CI
Orion Corporation Approves Dividend for the Financial Year Ended 31 December 2023, Payable on 3 April 2024 and 23 October 2024	03-20	CI
Transcript : Orion Oyj - Shareholder/Analyst Call	03-20
Orion Unveils Partnership with Save the Children Finland	02-22	MT
Orion Explores Potential Outsourcing of Kuopio Plant’s Production Operations	02-19	MT
Transcript : Orion Oyj, 2023 Earnings Call, Feb 13, 2024	02-13
Orion Provides FY24 Sales, Operating Profit Guidance	02-13	MT
Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member	02-13	CI

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Orion Oyj

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.76 EUR

Average target price

38.6 EUR

Spread / Average Target

-5.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION OYJ	+3.79%	6.26B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Orion Oyj

Equities

ORNBV

FI0009014377

Pharmaceuticals

Orion Looks For Possible Sale Of Subsidiary Orion Diagnostica Oy

Latest news about Orion Oyj

Chart Orion Oyj

Company Profile

Income Statement Evolution

Ratings for Orion Oyj

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals